Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 235Precursor Cell Lymphoblastic Leukemia-Lymphoma 69Recurrence 36Burkitt Lymphoma 34Leukemia 32Lymphoma 30Neoplasms, Plasma Cell 22Lymphoma, Non-Hodgkin 19Immunoglobulin Light-chain Amyloidosis 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Lymphoma, Mantle-Cell 16Neoplasms 15Nausea 15Lymphoma, Large B-Cell, Diffuse 15Vomiting 14Hodgkin Disease 13Breast Neoplasms 12Waldenstrom Macroglobulinemia 11Leukemia, Biphenotypic, Acute 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Amyloidosis 10Lung Neoplasms 9Smoldering Multiple Myeloma 8Prostatic Neoplasms 8Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Hematologic Neoplasms 7Blast Crisis 7Lymphoma, T-Cell, Cutaneous 6

Interventions

siltuximab 4tocilizumab 3fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2talquetamab 1otelixizumab 1obinutuzumab 1lopinavir-ritonavir drug combination 1glofitamab 1axicabtagene ciloleucel 1Piperacillin, Tazobactam Drug Combination 1Oxygen Inhalation Therapy 1Oxaliplatin 1Neuropsychological Tests 1Metoprolol 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Lopinavir 1Leukapheresis 1Infliximab 1Hydroxychloroquine 1Heparin, Low-Molecular-Weight 1Gemcitabine 1Gelsolin 1Etanercept 1Dexamethasone 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cytokine Release Syndrome × Calcium Dobesilate × Clear all
NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡